Stem Cell Therapy and Its Application to AMD: A Complete Review

By: Aiswharyaa Lalgudi Nagarajan

Abstract:

In recent years, exploring stem cell applications in ocular medicine has emerged as a revolutionary frontier in regenerative therapies. With their versatile potential, stem cells undergo extensive research for many diseases; however, their profound impact is particularly promising in ocular medicine. This paper aims to provide a comprehensive synthesis and analysis of existing research on stem cell therapy in ocular medicine, emphasizing two distinct approaches: direct and vesicular stem cell therapy. Of particular focus is age-related macular disease (AMD), a prevalent global ocular ailment lacking a definitive cure. With technological advancements escalating the risk of AMD across diverse demographics due to the prolonged use of electronics and the general extension of human life, the imperative for effective therapeutic solutions is heightened. With their manipulability, stem cells emerge as a prospective solution for addressing the complexities of ocular disorders. By delving into direct stem cell therapy and vesicular stem cell therapy, this paper endeavors to elucidate the potential, gaps, and evidence surrounding stem cells in the context of ocular medicine.

The synthesis highlights the promising potential of stem cell therapy, particularly in enhancing visual acuity and promoting integration into the ocular microenvironment. Consensus across various studies emphasizes the transformative impact of stem cells in ocular medicine. However, gaps remain in the robustness and diversity of research in this field. Long-term data is needed to assess the durability and sustainability of stem cell-based treatments. The variability in treatment protocols, including differences in cell types, transplantation methods, and patient conditions, underscores the need for standardization to yield consistent results. Immune rejection, especially with allogenic stem cells, remains a concern, and further research is required to improve compatibility with host tissue. Additionally, more investigation is needed into the survival and functionality of stem cells post-transplantation, mainly to ensure long-term viability. Optimizing the controlled differentiation of stem cells into desired cell types is crucial for achieving successful outcomes. Patient-specific factors, such as genetic background, age, and disease stage, require more exploration to tailor therapies effectively. Finally, ethical and regulatory challenges, particularly concerning genetic modifications or embryonic stem cells, call for continued research to ensure safety and compliance. This paper contributes to the ongoing discourse on stem cell-based approaches in ocular medicine and offers insights that may guide future breakthroughs.

Keywords: stem cell therapy, ocular medicine, age-related macular disease, regenerative medicine, visual acuity, vesicular stem cell therapy.

Introduction:

Many ocular diseases can impair vision, and many of these can be treated with stem cell therapies, including age-related macular degeneration (AMD). In this disease, the central macula is damaged, which causes blurred vision. The macula is the most sensitive tissue in the eye and is responsible for the clarity of one's vision. When the macula is damaged due to age and several other factors, it can cause severe vision loss and significantly decrease patients' quality of life. Two distinct types of AMD affect the macula: dry and wet. Dry AMD is when the macula thins as the patient ages, while wet AMD is when blood vessels grow in a way that damages the macula (National Eye Institute).



Figure 1: Anatomy of a Macula (Cleveland Clinic)

Furthermore, dry AMD can, at any point, cause wet AMD. In this research paper, while we studied stem cells' effects more on wet AMD, the takeaways could also help those with dry AMD. AMD is a progressive disorder; it takes many years for patients to notice symptoms. When symptoms occur, many see objects as blurrier, and lines and colors may look blurry and curved. (Cleveland Clinic). AMD is standard, with about 1 in 10 Americans aged 50 and older experiencing late AMD and 1 in 100 Americans experiencing early AMD. Many people are experiencing this problem, and more and more people will continue to do so because of the advent of technology. As technology advances, there is an

increasing amount of time spent engaging with digital screens for various activities, including work, entertainment, and communication. Prolonged exposure to screens, particularly at close distances, can contribute to digital eye strain, which may exacerbate pre-existing ocular conditions and potentially accelerate the development of macular degeneration over time.

Furthermore, the aging global population and longer life expectancies will likely result in a higher incidence of age-related macular degeneration (AMD) as individuals live longer lives. The cumulative effects of prolonged screen exposure and sedentary lifestyles associated with technology use may further compound the risk of retinal degeneration. Limited outdoor activity and reduced natural light exposure, both commonly associated with increased screen time, have been shown to affect retinal health negatively, potentially contributing to the onset and progression of AMD. Therefore, as technological engagement continues to increase, the prevalence of AMD may rise due to a combination of lifestyle factors and environmental influences.

Currently, there is no cure or treatment for AMD. Some supplements or medications slow their progress, but no treatment can stop or reverse the damage. Current recommended treatments include a healthy lifestyle: exercise, healthy food, and dietary supplements. Most of the time, these treatments can only slow damage to the macula. A long-term solution is needed(Carneiro and Andrade, 2017). There are some treatments for wet AMD, such as anti-VEGF and photodynamic therapy; however, these solutions are not applicable to dry AMD (National Eye Institute). This highlights the need for an effective and efficient treatment for this global disease. Stem cell therapy is promising and could be a very effective tool to help treat this common disease.

There are two methods in which stem cell therapy can be used to treat AMD: direct and indirect cell therapy through vesicular therapy. In direct cell therapy, stem cells or stem cell-derived tissue are directly implanted into the eye. In the studies discussed in this paper, most direct stem cell therapy is based on stem cell-derived retinal pigment epithelium cells (RPE cells). Many diverse sources and types of stem cells can give rise to RPE cells. These cells are among the most crucial cells affected by AMD. When transplanted, they can help replace damaged cells in the macula. Likewise, vesicular therapy is also an up-and-coming technique to help treat AMD. Mesenchymal stem cells are used in this technique. These cells are stem cells found in the placenta, so they have natural methods to help avoid the immune response from the mother. Because of this, researchers can use exosomes or extracellular vesicles derived from these stem cells to treat the macula. The exosomes release bioactive agents such as proteins, lipids, and nucleic acids (miRNAs, lncRNAs), which help the macula reverse the damage in the eye. While the bioactive components have not yet been identified, the results of these data are compelling.
In this paper, we will explore the use of stem cell therapy and vesicular therapy for AMD and similar ocular diseases. We will see the results of studies conducted using these methods and where further research needs to be done.

Direct Cell Therapy

One of the more straightforward therapies being developed is direct cell therapy, where stem cells are directly transplanted into the eye to help treat the disease. Direct cell therapy involves transplanting healthy, functional cells into damaged tissues to repair or replace dysfunctional or dead ones. The basic principle behind this therapy is to use live cells as a therapeutic agent to restore normal function in the affected area. These cells can come from various sources, such as stem cells, differentiated cells, or cells from the same individual (autologous) or a donor (allogeneic). Stem cells, in particular, are commonly used due to their ability to differentiate into various cell types and promote healing by releasing factors that reduce inflammation and encourage tissue regeneration. In the case of ocular diseases, like retinal disorders, direct cell therapy typically involves injecting cells, such as retinal progenitor cells (RPCs) or mesenchymal stem cells (MSCs), directly into the retina to support tissue repair, reduce cell death, and restore vision. However, one of the main challenges of direct cell therapy is ensuring that the transplanted cells survive, integrate into the tissue, and function properly without causing unwanted immune reactions or side effects such as tumor formation.



Figure 2: The Eye and Stem Cells (Eurostemcell)

RPE cells are more accessible and effective than other ocular cells. RPE cells are well-studied; they are easy to sustain in a lab setting and do not need to form synaptic connections with the body to complete their job. This makes them the obvious target for the treatment of degenerative ocular diseases. As shown, RPE cells have a vital role in the eye; they affect many parts of our vision and are a critical

factor in many ocular diseases, such as macular degeneration, retinitis pigmentosa, Stargardt disease, and diabetic retinopathy. So, RPE transplantation has a promising future in treating eye diseases, as it could help prevent further damage to different parts of the eye.

One method being engineered in the study by Michiko Mandai et al. is where induced pluripotent stem cells (iPSCs) are engineered to create a thin sheet of retinal pigment epithelial tissue or RPE tissue. This is then implanted into the eye and helps to replace or regrow damaged tissue. In this study, the researchers took skin cells from the patients and converted these cells into iPSCs. Then, they allowed these new cells to differentiate into retinal pigment epithelial cells or RPEs before transplanting (Mandai et al.). In the study "Transplantation of human pluripotent stem cell-derived retinal sheet in a primate model of macular hole," by Yasuaki Iwama et al., researchers transplanted human embryonic stem cell (hESC)-derived retinal organoid (RO) sheets into a non-human primate model of macular hole (MH). The results showed successful macular hole closure with continuous filling by the RO sheet. Although no synaptic connections between the host and graft were observed, the fovea's visual function, particularly the central part of the retina responsible for sharp central vision, and electrophysiological responses improved after the transplantation. The procedure demonstrated the development of rod and cone photoreceptors in the grafted tissue. The transplanted cells survived and matured despite mild immune rejection, managed with focal steroid injections. These findings suggest that hESC-derived RO sheet transplantation may be a practical therapeutic option for refractory macular hole cases, providing an alternative to traditional surgical methods and potentially improving outcomes in retinal repair.

For several reasons, mesenchymal stem cells (MSCs) are easier to use in therapeutic applications. First, they are relatively easy to isolate from bone marrow, adipose tissue, and umbilical cord blood, making them widely accessible. One of the main benefits of MSCs is their ability to be easily preserved through cryopreservation, allowing them to be stored for long periods without losing viability. Even after thawing, these cells can be successfully differentiated into various cell types, maintaining their therapeutic potential (Ginis, Grinblat, and Shirvan, 2011). MSCs also have strong immunomodulatory properties, meaning they can reduce inflammation and suppress immune responses, which is beneficial for preventing rejection in cell-based therapies.

Additionally, unlike embryonic stem cells (ESCs), MSCs do not carry the same ethical concerns or risks of tumor formation, making them a safer option for clinical use. MSCs are also multipotent, meaning they can differentiate into various cell types such as bone, cartilage, and fat, and they secrete extracellular vesicles (EVs) that carry proteins, microRNAs, and growth factors, further enhancing their therapeutic potential. Their low immunogenicity and ability to integrate into different environments make MSCs particularly advantageous for regenerative medicine and cell therapy.

Furthermore, this method is a promising treatment for AMD because RPE cells have successfully been used to treat similar ocular diseases. Many recent studies have shown that RPE transplantation in the eye can improve vision by preventing photoreceptors from further damage. In seminal experiments by Li and Turner in 1988, it was found that when they transplanted RPE cells into the Royal College of Surgeons (RCS) rats, a genetically modified strain of rats known for their retinal degeneration, the rats'

eyes had preserved the outer nuclear, plexiform, and photoreceptors from further damage (Li and Turner). Since then, transplantation has been studied and has had positive results for humans with non-vascular AMD. In another study by Schwartz and team, researchers targeted dry AMD using hESC-derived RPE cells in the eye. When implanted into human patients, RPE cells showed no deterioration or adverse effects such as tumor growth. After the implantation, more than half the patients had improved visual acuity, and more than 70% had increased pigmentation in the subretinal space (Schwartz et al.). The visual acuity improved from basic hand motions to 20/800 in the patients with Stargardt's macular dystrophy, where 20/800 is a measure of visual clarity on the Snellen chart, representing very low vision. In patients with dry AMD, the vision improved from 21 ETDRS (Early Treatment Diabetic Retinopathy Study) letters to 28, where the ETDRS scale is used to quantify visual acuity based on the number of letters a patient can read on a standardized eye chart. These results suggest that RPE cell transplantation may significantly enhance visual outcomes in patients with retinal degenerative diseases like Stargardt's macular dystrophy and dry AMD. Overall, these findings demonstrate the potential of RPE cell therapy as a promising treatment for preserving and improving vision in patients with retinal diseases. This method is emerging because the RPE stem cell type can be derived from multiple cell types and frozen, and the differentiation process is relatively simple. Recent studies show that mesenchymal stem cells (MSCs) and other stem cells can be isolated from many sources and then differentiated into RPE cells. It has been found that embryonic stem cells, or ESCs, can spontaneously differentiate into RPE cells. ESCs have also been differentiated into RPE-like cells by adherent culturing. RPE cells were implanted into RPE degeneration rats. The implanted cells increased the survival of photoreceptors in the eye(Nair et al.).

Moreover, this method has many advantages, such as its simplicity, efficacy, and lack of exogenous reagent usage. This can also be implemented in a human model. When a similar process was used with human ESCs in the rats, the cells were well integrated into the host and eventually showed many visual improvements(M'Barek et al.). The most important advantage of this technique is that no exogenous reagents were used, which makes the entire process simpler and more accessible(Dang et al.). Overall, this method presents a highly feasible and efficient approach for retinal therapies due to its straightforward process and the absence of exogenous reagents, making it easier to implement. With ongoing research, this approach holds great potential for future applications in human models, paving the way for more accessible and effective treatments for retinal diseases. This method has been tested for correct integration into the microenvironment and potential tumorigenicity. Moreover, it was found that transplanted cells integrated well into the ocular microenvironment (Feng et al.). In this study, the implanted cells showed no malignant growth and assimilated well into the microenvironment (Feng et al.).

In a survey by Petrus-Reurer et al., hESC-derived RPE cells were implanted into rabbits in the subretinal region (Petrus-Reurer et al.). Additionally, hESC-RPE monolayers were implanted in the subcutaneous layer of the mice. After monitoring the mice for seven months, they found no malignant growth, and the remaining cells were pigmented and carried the markers that RPE cells usually have (IBID). This indicates that the implanted hESC-derived RPE cells did not differentiate or become cancerous. There was no apoptosis in the eyes treated with RPE cells when compared with untreated eyes,

where there was apoptosis. The rabbits were examined four weeks after transplantation; none of the transplanted cells were rejected, and there was no tumor growth (Petrus et al.).When implanting the mature hESC-derived RPE tissue into the mice, none of the mice ever showed any sign of abnormal growth (Petrus et al.). In this study, the distribution of the transplanted cells was also measured (Petrus et al.). The researchers found that the transplanted cells stayed in the eye and did not migrate to other body parts (Petrus et al.).

In a similar study by Wang et al., researchers implanted RPC cells derived from hESCs into the ganglion cell layer. It was found that these cells started carrying the markers of the local cells called Brn3a. Moreover, the thickness of the outer nuclear layer also increased in the eye. The RPC (or human retinal pigment cells) also expressed a neural stem cell marker Nestin and two retinal progenitor cell markers, Pax 6 and Chx 10 ((Wang et al.). This indicates that the transplanted cells are well integrated into the microenvironment. After 16 weeks of transplantation, there was no teratoma formation in the two groups injected with hRPCs compared to the positive control(Wang et al.). Comparable results were achieved when non-human primate models were used in similar transplant experiments (Aboualizadeh et al.).

In a study by Aboualizadeh et al., researchers used fluorescently tagged hESCs (hESC-CRX+/tdTomato cells) and transplanted them into the subretinal area of two non-human primates (Aboualizadeh et al.). The researchers found that these cells made synaptic connections with the host cells (Aboualizadeh et al.). In a study by Tu et al., iPSC-derived retinas were implanted into rats and primates. These cells were introduced in rats with rhodopsin mutant SD-Foxn1 Tg(S334ter)3LavRrrc, a genetically modified rat model known for its mutation in the S334ter gene, which causes retinal degeneration similar to human retinitis pigmentosa. Additionally, the study included monkeys with laser-induced photoreceptor degeneration, mimicking the condition in humans. They found that many retinal grafts survived in the rats for up to five months and in the monkeys for as long as two years (Tu et al.). Almost 60% of the transplanted rat retinas responded to light stimuli through retinal ganglion cells (RGCs), indicating functional integration of the transplanted cells. For monkeys, after 1.5 years, there was also a slight recovery of visual acuity as measured by a Landolt ring-based visual acuity test, which is both easy to administer and effective for evaluating visual function in primates (Tu et al.). Much evidence proves that stem cell-derived retinal transplants integrate well into the ocular environment without risk of tumor formation, indicating that this could be a viable treatment method.

Vesicular Therapy

Vesicular therapy in the context of stem cells mainly focuses on MSCs. These stem cells are multipotent in various parts of the human body. They can also suppress the immune system by emitting inhibitors, which stop the cytokine signaling from the macrophages. In vesicular therapy, the MScs are isolated and conditioned to produce MSc-Evs. First, the MSCs are extracted from the umbilical cord's bone marrow, placenta, and adipose tissue. Then, the MSCs are conditioned and cultured to release the EVs. Using different isolation techniques, we can isolate the EVs from the MSCs and quantify and characterize them. Then, these MSCs are implanted into the part of the body that needs regeneration.

Since these extracellular vesicles contain many bioactive chemicals, they aid in the eye's healing and regeneration. Reducing inflammation and preventing cell death is critical for protecting retinal health, especially in conditions that lead to vision impairment. This is an introductory sentence (including that this is about reducing inflammation and cell death). In a study by Biji Mathew et al., the researchers studied the effects of MSC-EVs in retinal ischemic-reperfusion injury. This condition is when blood flow to the retina is stopped and restored. This causes damage to the retina and other ocular tissues, resulting in vision impairment. The researchers first tested in vitro models using R28 cells and MSC-EVs. Then, they started in vivo experiments using a rat model and MSC-EVs. In the end, the researchers found that the MSC-EVs could help heal and protect R28 cells when subjected to conditions like ischemic-reperfusion injury; it was found that the cytotoxicity significantly reduced. Firstly, in the in vitro model, it was found that these EVs help decrease cell death and are internalized into the cell. In the study, the researchers found that the MSC-EVs were endocytosed by the R28 cells. This means the EVs were taken into the cell and integrated into the host cells.

Further imaging showed staining in the cytoplasm and near the nuclei, meaning the cells were efficiently internalized. Like the in-vitro model, even in the in-vivo model, the EVs were taken up by retinal neurons, ganglion cells, and microglia. In the in vivo model, it was found that 24 hours had passed after the injection of the MSC-EVs, and there was a recovery in the a and b wave amplitudes of the electroretinogram compared to the control. TNF-a and IL-6 (inflammatory mediators) had a significant reduction after the treatment. There was also a substantial decrease in cleaved caspase-3 in the treated ischemic retina. These proteins are usually indicators of apoptosis and inflammation; since they have been reduced, MSC-EVs reduce cell death and damage in the retina. Given the ability of MSC-EVs to reduce inflammation and protect retinal cells, this approach could also be explored for conditions like age-related macular degeneration (AMD), where retinal damage and inflammation play a crucial role in disease progression.

Introducing specific healing proteins and microRNAs to treat retinal damage has shown promising results in reducing inflammation and cell death—introductory sentence (vesicular therapy to deliver targeted therapy). For example, in a study by Fengtian Sun et al., the researchers used Mesenchymal stem cells as a blister on the eye. They found that instead of just using MSCs as the healing tool, MSCs-Ev allows us to introduce more specific healing proteins and microRNAs. For example, in this study by Fengtian Sun, the researchers used a diabetic rat model and injected the MSC-sEVs into them. Then, the responses of the cell signal pathways along with the RPE Cells were analyzed in the experiment. In the end, researchers found that MSc-sEvs reduced retinal cell death. It also helped heal and grow more RPE cells in the eye. It was found that the EVs delivered NEDD4 to the eye. Ultimately, this set off the PTEN/AKT/NRF2 regulation, which eventually helped heal the retinal damage and alleviate diabetic retinopathy. The intravitreal injection of the EVs had an antioxidant effect, which decreased retinal cell damage and death. The treatment also helped the proliferation or growth rate of oxidative stress. Since the experiment was done in a high-glucose environment, there is increased stress in these cells.

Additionally, a protein called PTEN becomes more active and causes more damage. When these MSC-EVs were released, it was found that they decreased the amount of PTEN and increased the activity of AKT and NRF2, which are necessary in helping heal the eyes. Further studies found that all this was due to a protein called NEDD4 carried in EVs. This protein restores cell pathways because when it helps break down PTEN, it signals the activation of AKT and NRF2. Finally, when the researchers evaluated the same experiment without the NEDD4, it showed little to no effect on treating the damage. Given the antioxidant effects and the ability of MSC-EVs to specifically target cell signaling pathways, this therapeutic approach holds great potential for treating diabetic retinopathy and other retinal diseases.

According to current research findings, extracellular vesicle (EV) treatment is viable for treating ocular illnesses. These microscopic vesicles have a fantastic ability to carry a variety of bioactive compounds, such as proteins and nucleic acids, which helps them deliver therapeutic payloads to target cells. Research has demonstrated the potential of extracellular vesicles (EVs) produced from many cell types, such as mesenchymal stromal cells (MSCs), retinal pigment epithelium cells, or endothelial cells, to treat disorders like diabetic retinopathy and corneal damage. EVs function in various ways, including promoting tissue regeneration, reducing inflammation, and enhancing cell survival. Their involvement in nerve regeneration in eye illnesses is remarkable; in animal models of optic nerve injury and glaucoma, MSC-derived EVs have been shown to facilitate axonal regeneration and functional recovery. Numerous neurotrophic factors and cytokines found in these cysts promote angiogenesis, control inflammation in the retina and optic nerve, and support the survival and regeneration of neurons.

Furthermore, EVs' potential as a vehicle for delivering therapeutic compounds has been demonstrated in experimental models, highlighting their potential for treating ocular illnesses. However, there are obstacles to how EV-based therapeutics are being clinically translated; more preclinical and clinical research is required to realize their therapeutic potential fully and overcome current barriers. In summary, EV treatment presents a strong possibility for treating regeneration disorders.

Gaps and Controversy

Despite promising direct and extracellular stem cell treatments for age-related macular degeneration (AMD), there are several significant gaps. Of greatest concern are the safety of stem cell differentiation, especially the potential for off-target effects or failure of full maturation. Tumorigenicity continues to be a significant limitation since uncontrolled cell division can damage patients. Moreover, the long-term consequences of these treatments are still unknown, with risks like immune rejection and inflammation that differ based on whether the source of stem cells is autologous or allogeneic. Adding to these challenges, most available studies have small populations, making generalizability and reliability of findings questionable. Being one of the stem cell safety problems, their unpredictability is one such issue. For example, there have been instances when it was found that there was unintended MSC differentiation. They can sometimes differentiate into tissues like bone or cartilage, harming the recipient. Further, the risk of tumors was investigated at an initial level, and this is an issue that must be studied in depth.

Researchers have also discovered in another study that MSCs can differentiate into endothelial cells and create a capillary network. This can lead to neovascularization, which is a severe condition. In a

recent study, they tested three women with macular degeneration, and after receiving bilateral intravitreal injections of adipose-derived stem cells, they all experienced blindness. In this study, high rates of retinal detachment also occurred, with a rate of 29% in phase 1 and 15% in phase 1- 2a(Kuriyan et al.). Furthermore, these MSCs could also promote tumorigenicity. Some studies found that the MSCs suppressed the anti-tumor immune response, increasing tumor growth. Since MSCs have natural immune system suppressors, we have no control over them when they decide to go rogue. It was found that MSCs promote the polarization of the immune system in the anti-inflammatory TH2 pathway. This creates an environment where the immune system is suppressed, allowing the proliferation of tumor cells.

Further research could focus on the long-term effects of transplantation. As demonstrated by the evidence, one of the most significant findings is that studies showing improvement tend to be temporary. In many studies, visual acuity or retinal function improvements are observed within a few months to a year after transplantation, but these benefits often diminish over time. This is primarily due to the short-term nature of most studies, which typically track patients for a limited period, usually only one to two years. While early-phase clinical trials and animal studies have shown promising results, they focus on short-term outcomes such as safety, initial integration of transplanted cells, and temporary visual improvements. There is insufficient data on the long-term durability of these improvements, with questions remaining about whether transplanted cells maintain their functionality or integrate effectively with the host tissue over time. More research, observation, and experimentation are required to demonstrate that stem cell therapy can yield lasting benefits. One approach to achieving this goal is by integrating various techniques. Much of this field's research is conducted independently, each with specific methods. However, combining transplantation methods and techniques could yield long-term benefits.

Finally, the limited sample size is another significant gap in this field. Many studies are conducted with small sample sizes, including some non-human primate studies, where only two test subjects are involved. Early-phase clinical trials, which primarily focus on assessing safety and feasibility, often include smaller cohorts. For example, a study by Schwartz et al. involved two patients with severe exudative AMD who received subretinal transplants and showed improved vision over 12 months (Singh and MacLaren). Similarly, a Phase I/IIa trial by the National Eye Institute (NEI) aimed to enroll up to 12 participants to evaluate the safety of autologous induced pluripotent stem cell-derived retinal pigment epithelium transplantation for geographic atrophy associated with AMD (Rohowetz and Koulen). Stem cell therapy holds significant potential in treating AMD and other retinal diseases. However, it is equally clear that more comprehensive and specific research is needed in this area. Larger sample sizes and a broader range of techniques should be employed in these studies.

Future Directions

In conclusion, exploring stem cell therapy for ocular diseases reveals a landscape brimming with promise and potential. Numerous studies have underscored the efficacy of stem cell interventions, showcasing their ability to treat ocular conditions and improve visual acuity. Moreover, the remarkable adaptability of stem cells to integrate into the retinal microenvironment and establish neural connections further solidifies their utility in ocular therapeutics. However, amidst these promising findings, it is

imperative to acknowledge the existing gaps and challenges within the field. The prevalence of low sample sizes in many studies, the need for standardized methodologies, and the increased in vivo research with larger sample sizes highlight areas for improvement. Addressing these limitations is essential to bolstering stem cell research's robustness and reproducibility in ocular disease treatment.

Fortunately, solutions are within reach. By prioritizing robust studies with higher sample sizes and advocating for integrating enhanced research methodologies, we can fortify the foundation upon which stem cell therapy stands. Furthermore, leveraging promising previous studies with larger sample sizes can guide future investigations, facilitating a comprehensive exploration of potential side effects and their mitigation strategies. As we navigate these challenges and opportunities, we must maintain optimism about the future of stem cell therapy in ocular diseases. Despite the hurdles, the overall outlook remains bright, with continued research efforts poised to drive validation and implementation forward. With concerted dedication and collaboration, stem cell therapy promises to address unmet medical needs in ocular disease treatment, offering hope to countless individuals worldwide.

Works Cited

Abbaszadeh, H., et al. "Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Novel Therapeutic Paradigm." *Journal of Cellular Physiology*, vol. 235, no. 2, 2019, pp. 706–717. https://doi.org/10.1002/jcp.29004.

Aboualizadeh, Ebrahim, et al. "Imaging Transplanted Photoreceptors in Living Nonhuman Primates with Single-Cell Resolution." *Stem Cell Reports*, vol. 15, no. 2, July 2020, pp. 482–497. https://doi.org/10.1016/j.stemcr.2020.06.019.

Cleveland Clinic. "Macula: What It Is." *Cleveland Clinic*, 10 Feb. 2025, my.clevelandclinic.org/health/body/23185-macula.

Dang, Yalong, et al. "Stem Cell Therapies for Age-Related Macular Degeneration: The Past, Present, and Future." *Clinical Interventions in Aging*, Jan. 2015, pp. 255–264. https://doi.org/10.2147/cia.s73705.

Feng, Xia, et al. "Transplanted Embryonic Retinal Stem Cells Have the Potential to Repair the Injured Retina in Mice." *BMC Ophthalmology*, vol. 21, no. 1, Jan. 2021. https://doi.org/10.1186/s12886-020-01795-1.

Fronk, A. H., and E. Vargis. "Methods for Culturing Retinal Pigment Epithelial Cells: A Review of Current Protocols and Future Recommendations." *Journal of Tissue Engineering*, vol. 7, 2016. https://doi.org/10.1177/2041731416650838.

Hushmandi, Kiavash, et al. "Gene Therapy for Age-Related Macular Degeneration: A Promising Frontier in Vision Preservation." *Cell Communication and Signaling*, vol. 23, no. 1, May 2025. https://doi.org/10.1186/s12964-025-02246-4.

Iwama, Yasuaki, et al. "Transplantation of Human Pluripotent Stem Cell-Derived Retinal Sheet in a Primate Model of Macular Hole." *Stem Cell Reports*, Oct. 2024. https://doi.org/10.1016/j.stemcr.2024.09.002.

Jiang, L., et al. "Cyclic Cell-Penetrating Peptide-Engineered Ceria Nanoparticles for Non-Invasive Alleviation of Ultraviolet Radiation-Induced Cataract." *Journal of Nanobiotechnology*, vol. 23, no. 1, 2025. https://doi.org/10.1186/s12951-025-03402-1.

Kaur, K., et al. "Digital Eye Strain—A Comprehensive Review." *Ophthalmology and Therapy*, vol. 11, no. 5, 2022, pp. 1655–1680. https://doi.org/10.1007/s40123-022-00540-9.

Kuriyan, Ajay E., et al. "Vision Loss after Intravitreal Injection of Autologous 'Stem Cells' for AMD." *New England Journal of Medicine*, vol.. 376, no. 11, Mar. 2017, pp. 1047–1053. https://doi.org/10.1056/nejmoa1609583.

Li, Linxi, and James E. Turner. "Optimal Conditions for Long-Term Photoreceptor Cell Rescue in RCS Rats: The Necessity for Healthy RPE Transplants." *Experimental Eye Research*, vol. 52, no. 6, June 1991, pp. 669–679. https://doi.org/10.1016/0014-4835(91)90019-b.

Liang, W., et al. "Mesenchymal Stem Cells as a Double-Edged Sword in Tumor Growth: Focusing on MSC-Derived Cytokines." *Cellular & Molecular Biology Letters*, vol. 26, no. 1, 2021. https://doi.org/10.1186/s11658-020-00246-5.

Litts, K. M., et al. "Clinicopathological Correlation of Outer Retinal Tubulation in Age-Related Macular Degeneration." *JAMA Ophthalmology*, vol. 133, no. 5, 2015, p. 609. https://doi.org/10.1001/jamaophthalmol.2015.126.

Maaijwee, K., et al. "Retinal Pigment Epithelium and Choroid Translocation in Patients with Exudative Age-Related Macular Degeneration: Long-Term Results." *Graefe's Archive for Clinical and Experimental Ophthalmology*, vol. 245, no. 11, 2007, pp. 1681–1689. https://doi.org/10.1007/s00417-007-0607-4.

Ma, Y., et al. "Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Improve Nerve Regeneration after Sciatic Nerve Transection in Rats." *Journal of Cellular and Molecular Medicine*, vol. 23, no. 4, 2019, pp. 2822–2835. https://doi.org/10.1111/jcmm.14190.

Mandai, Michiko, et al. "Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration." *New England Journal of Medicine*, vol.. 376, no. 11, Mar. 2017, pp. 1038–1046. https://doi.org/10.1056/nejmoa1608368.

Mathew, Biji, et al. "Mesenchymal Stem Cell-Derived Extracellular Vesicles and Retinal Ischemia-Reperfusion." *Biomaterials*, vol. 197, Jan. 2019, pp. 146–160. https://doi.org/10.1016/j.biomaterials.2019.01.016.

M'Barek, Karim Ben, et al. "Human ESC–Derived Retinal Epithelial Cell Sheets Potentiate Rescue of Photoreceptor Cell Loss in Rats with Retinal Degeneration." *Science Translational Medicine*, vol. 9, no. 421, Dec. 2017. https://doi.org/10.1126/scitranslmed.aai7471.

Nair, Deepthi S. Rajendran, et al. "Long-Term Transplant Effects of iPSC-RPE Monolayer in Immunodeficient RCS Rats." *Cells*, vol.. 10, no. 11, Oct. 2021, p. 2951. https://doi.org/10.3390/cells10112951.

Nassiri, S. M., and R. Rahbarghazi. "Interactions of Mesenchymal Stem Cells with Endothelial Cells." *Stem Cells and Development*, vol. 23, no. 4, 2014, pp. 319–332. https://doi.org/10.1089/scd.2013.0419.

National Eye Institute. *Age-Related Macular Degeneration (AMD) | National Eye Institute*. 22 May 2025, www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration.

Petrus-Reurer, Sandra, Hammurabi Bartuma, et al. "Subretinal Transplantation of Human Embryonic Stem Cell Derived-Retinal Pigment Epithelial Cells into a Large-Eyed Model of Geographic Atrophy." *Journal of Visualized Experiments*, no. 131, Jan. 2018. https://doi.org/10.3791/56702.

Petrus-Reurer, Sandra, Nerges Winblad, et al. "Generation of Retinal Pigment Epithelial Cells Derived from Human Embryonic Stem Cells Lacking Human Leukocyte Antigen Class I and II." *Stem Cell Reports*, vol. 14, no. 4, Mar. 2020, pp. 648–662. https://doi.org/10.1016/j.stemcr.2020.02.006.

Rohowetz, Landon J., and Peter Koulen. "Stem Cell-Derived Retinal Pigment Epithelium Cell Therapy: Past and Future Directions." *Frontiers in Cell and Developmental Biology*, vol. 11, Mar. 2023. https://doi.org/10.3389/fcell.2023.1098406.

Sanghani, A., et al. "Advances in Exosome Therapies in Ophthalmology—From Bench to Clinical Trial." *Acta Ophthalmologica*, vol. 100, no. 3, 2021, pp. 243–252. https://doi.org/10.1111/aos.14932.

Schwartz, Steven D., et al. "Embryonic Stem Cell Trials for Macular Degeneration: A Preliminary Report." *The Lancet*, vol. 379, no. 9817, Jan. 2012, pp. 713–720. https://doi.org/10.1016/s0140-6736(12)60028-2.

Seyedrazizadeh, S., et al. "Extracellular Vesicles Derived from Human ES-MSCs Protect Retinal Ganglion Cells and Preserve Retinal Function in a Rodent Model of Optic Nerve Injury." *Stem Cell Research & Therapy*, vol. 11, no. 1, 2020. https://doi.org/10.1186/s13287-020-01702-x.

Singh, Mandeep S., and Robert E. MacLaren. "Stem Cell Treatment for Age-Related Macular Degeneration: The Challenges." *Investigative Ophthalmology & Visual Science*, vol. 59, no. 4, July 2018, p. AMD78. https://doi.org/10.1167/iovs.18-24426.

Strauss, O. "The Retinal Pigment Epithelium in Visual Function." *Physiological Reviews*, vol. 85, no. 3, 2005, pp. 845–881. https://doi.org/10.1152/physrev.00021.2004.

"The Eye and Stem Cells: The Path to Treating Blindness." *EuroStemCell*, www.eurostemcell.org/eye-and-stem-cells-path-treating-blindness.

Tu, Hung-Ya, et al. "Medium- to Long-Term Survival and Functional Examination of Human iPSC-Derived Retinas in Rat and Primate Models of Retinal Degeneration." *EBioMedicine*, vol. 39, Nov. 2018, pp. 562–574. https://doi.org/10.1016/j.ebiom.2018.11.028.

Wang, Song-Tao, et al. "Transplantation of Retinal Progenitor Cells from Optic Cup-Like Structures Differentiated from Human Embryonic Stem Cells In Vitro and In Vivo Generation of Retinal Ganglion-Like Cells." *Stem Cells and Development*, vol. 28, no. 4, Dec. 2018, pp. 258–267. https://doi.org/10.1089/scd.2018.0076.

Zhang, S., et al. "Global Burden of Low Vision and Blindness Due to Age-Related Macular Degeneration from 1990 to 2021 and Projections for 2050." *BMC Public Health*, vol. 24, no. 1, 2024. https://doi.org/10.1186/s12889-024-21047-x.